The Filing Desk

Monopar Therapeutics

MNPR · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

MNPR · Last close · November 19, 2026
$70.29
Value Monopar Therapeutics yourself

Monopar Therapeutics reported revenue of $0 million in fiscal 2025. It paid out $35 million in dividends and buybacks. The diluted share count rose 95.5%.

Monopar Therapeutics Inc. Latest fiscal year ended December 31, 2025 10-K filed March 27, 2026 · 0001437749-26-010025 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$14M
 
Free cash flow
—
 
Return on equity
−14.2%
37.2 pts
Market cap
$604M
Nov 19 close
P/E
—
 

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-5), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Monopar Therapeutics does

Monopar Therapeutics is a clinical-stage drug company, so it has no approved products. It is developing a treatment for Wilson disease and new radiopharmaceuticals for cancer. Radiopharmaceuticals are drugs that carry radioactive material to find or destroy tumor cells.

Its Wilson disease candidate is ALXN1840, a once-daily pill in late-stage development. Wilson disease is a rare genetic condition in which the body can't remove excess copper, which builds up in the liver and brain. ALXN1840 has Orphan Drug Designation in the U.S. and the EU and Fast Track designation. The company says its near-term focus is putting together a regulatory package and submitting a new drug application to the FDA.

Its cancer programs, MNPR-101-Zr, MNPR-101-Lu and MNPR-101-Ac, target a protein called uPAR found on some advanced cancers. They are at the imaging, early human-trial and late preclinical stages. Monopar builds its pipeline by research of its own and by licensing drugs from others, and it recently acquired the ALXN1840 program.

Its biggest risks, as it describes them

  • A short operating history, large expected losses and a high risk of never being profitable.
  • It may need more funding or pharmaceutical partners to continue its clinical programs.
  • Its recently acquired ALXN1840 program could face delays in development or in gaining approval.
  • Market conditions, including inflation, tariffs and geopolitical events, could affect its costs and its ability to raise money.
From Monopar Therapeutics's annual report on Form 10-K, filed March 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Monopar Therapeutics lost money in fiscal 2025: a net loss of $14 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments20121491123
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio13.0x4.2x4.2x11.5x51.4x
Quick ratio13.0x4.2x4.2x11.5x51.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Monopar Therapeutics' filings doesn't give both for any year, so free cash flow is left out.

Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Monopar Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $104,925 of Monopar Therapeutics shares on the open market, and 5 insiders sold $3.7 million, $3.4 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 24, 2026Chandler RobinsonChief Executive Officer, DirectorSold plan29,056$88.00$2.6 millionForm 4
Aug 26, 2026Kim R TsuchimotoDirectorSold plan4,090$111.39$455,567Form 4
Aug 26, 2026Patrice RiouxActing Chief Medical OfficerSold plan1$111.26$111Form 4
Aug 25, 2026Raymond AndersonDirectorSold plan3,142$111.77$351,189Form 4
Dec 26, 2025Quan Anh VuChief Financial OfficerBought1,500$69.95$104,925Form 4
Dec 18, 2025Arthur J KlausnerDirectorSold5,121$67.15$343,889Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''−26.4811.0953.62
Accruals ratio−5.3%−27.1%−1.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets——Fail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Monopar Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Monopar TherapeuticsFY25——————
Aardvark TherapeuticsFY25——————Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000————00
Revenue growth——————————
Gross profit——————————
Research and development012246861310
Operating income−1−17−3−4−6−9−10−9−16−17
Net income−1−17−3−4−6−9−10−8−16−14
Diluted EPS (US$)—−9.45−1.75−2.25−2.90−3.65————
Diluted shares (millions)—222222347
Cash flow
Cash from operations−1−3−3−3−5−7−7−8−6−12
Capital expenditure——————————
Free cash flow——————————
Dividends paid0000000000
Share buybacks00000000035
Acquisitions0000000000
Stock-based compensation0001122215
Balance sheet at fiscal year end
Cash and short-term investments297131720121491123
Debt incl. finance leases——————————
Total assets310713172013760141
Total liabilities0001123253
Shareholders' equity310713161910655138
Margins and ratios
Gross margin——————————
Operating margin——————————
Net margin——————————
Free cash flow margin——————————
Rule of 40 (growth + FCF margin)——————————
Return on capital——————————
Return on equity—−265.9%−39.0%−43.2%−44.5%−52.6%−72.4%−107.2%−51.4%−14.2%
Return on assets—−258.1%−37.4%−40.9%−41.7%−48.7%−62.3%−81.7%−46.1%−13.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Monopar Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Monopar Therapeutics.